[Hydrocortisone for the treatment of cerebral vasopasm--(1) experiments in dogs (author's transl)].
The usefulness of hydrocortisone for the treatment of cerebral vasospasm was investigated using dogs by measuring changes in cerebral arterial diameter in angiograms as well as in other parameters such as blood pressure, intracranial pressure and CBF. The intrathecal (50-300 mg) or intravenous (100 mg/kg) injection of hydrocortisone resulted in a marked dilatation of cerebral arteries both in control animals and vasospastic animals after subarachnoid hemorrhage. The intrathecal injection caused a temporary rise in blood pressure immediately following the injection. Cerebrospinal fluid pressure was increased progressively. On the other hand, the intravenous injection resulted in a fall in blood pressure and a transient rise in cerebrospinal fluid pressure. CBF showed a tendency to increase both with intrathecal and intravenous injection. With intravenous injection a high CSF level of cortisol was found 1 and 2 hours after the injection and it was correlated to the degree of cerebral arterial dilatation, indicating that a significant amount of hydrocortisone could penetrate into the CSF and dilate the intracranial vessels by its direct pharmacological action.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001810:Blood Volume / Q000187:drug effects; D002533:Cerebral Angiography; D002536:Cerebral Arteries / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006854:Hydrocortisone / Q000008:administration & dosage* / Q000627:therapeutic use; D007275:Injections, Intravenous; D007278:Injections, Spinal; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000008:administration & dosage*
D014665:Vasodilator Agents; D006854:Hydrocortisone